Expert Insights
Channels
Themes
Active ETFs
ETF Investing
Alternatives
ETF Strategist
Artificial Intelligence
ETF Yield
Beyond Basic Beta
Financial Literacy
China Insights
Fixed Income
Climate Insights
Free Cash Flow
Core Strategies
Innovative ETFs
Crypto
Institutional Income Strategies
Disruptive Technology
Leveraged & Inverse
Energy Infrastructure
Modern Alpha
ETF Building Blocks
Portfolio Construction
ETF Education
Tax Efficient Income
Asset Class
Equity
Emerging Market Equities
Int'l Developed
U.S. Equity
Fixed Income
High Yield Corporates
Int'l Fixed Income
Investment Grade Corporates
US Treasuries & TIPS
Alternatives
Commodities
Currency
Gold/Silver/Critical Minerals
Volatility
ETF Ecosystem
ETFs in Canada
Market Outlook
Exchange
Webcasts
Popular ETFs
SPY – SPDR S&P 500 ETF
VOO – Vanguard S&P 500 ETF
QQQ – Invesco QQQ ETF
GLD – SPDR Gold Shares ETF
IVV – iShares Core S&P 500 ETF
EFA - iShares MSCI EAFE ETF
EEM – iShares MSCI Emerging Markets ETF
IEMG – iShares Core MSCI Emerging Markets ETF
VTI – Vanguard Total Stock Market ETF
GDX - VanEck Vectors Gold Miners ETF
XLF - Financial Select Sector SPDR Fund
VEA – Vanguard FTSE Developed Markets ETF
VTV - Vanguard Value ETF
Top Gold ETFs
Top Oil ETFs
Top Commodity ETFs
Top Hedge Fund ETFs
Top Financials ETFs
Top Inverse Equities ETFs
Top High Yield Bond ETFs
Education & Media
Newsletter
New ETFs
Education Central
Videos
ETF of the Week Podcast
ETF Prime Podcast
Gaining Perspective
ETF 360 Video Series
Exchange
Events
Exchange
Fixed Income Symposium
Alternatives Symposium
Equity Symposium
Cryptocurrency Symposium
Market Outlook Symposium
Company
About VettaFi
Get VettaFi’ed
You are at:
Home
»
Equity ETFs
»
New Wave of Biosimilar Drugs May Boost Generics ETF
»
GNRX_ETF
GNRX_ETF
Max Chen
April 15, 2016
Load More
X